Sponsor

Boryung Pharmaceutical Co., Ltd

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Boryung Pharmaceutical Co., Ltd appears in 111 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials111
Recruiting shown9
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)NCT07083401 · lead sponsor · 2025-07-05
RECRUITING
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)NCT07083388 · lead sponsor · 2025-07-03
RECRUITING
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 DiabetesNCT06972732 · lead sponsor · 2025-06-11
RECRUITING
A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With SchizophreniaNCT06821945 · lead sponsor · 2025-05-30
RECRUITING
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination TherapyNCT06649162 · lead sponsor · 2024-09-30
RECRUITING
A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer PatientsNCT06537752 · lead sponsor · 2024-07-15
RECRUITING
Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ InjectionNCT06021483 · lead sponsor · 2023-08-16
RECRUITING
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and HypertensionNCT05970237 · lead sponsor · 2023-07-26
RECRUITING
An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZNCT05413057 · lead sponsor · 2022-06-23
RECRUITING
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.NCT07685054 · lead sponsor · 2026-08-01
NOT_YET_RECRUITING
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed ConditionsNCT07421414 · lead sponsor · 2026-04-19
NOT_YET_RECRUITING
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting ConditionsNCT07421401 · lead sponsor · 2026-04-13
NOT_YET_RECRUITING
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed ConditionsNCT07421388 · lead sponsor · 2026-04-09
NOT_YET_RECRUITING
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsNCT07421375 · lead sponsor · 2026-04-02
NOT_YET_RECRUITING
A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential HypertensionNCT07373613 · lead sponsor · 2026-03-01
NOT_YET_RECRUITING
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult VolunteersNCT06889012 · lead sponsor · 2025-05-07
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed ConditionsNCT06744439 · lead sponsor · 2025-01-09
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed ConditionsNCT06744062 · lead sponsor · 2025-01-05
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting ConditionsNCT06744426 · lead sponsor · 2025-01-04
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting ConditionsNCT06744127 · lead sponsor · 2025-01-03
COMPLETED
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed ConditionsNCT06890299 · lead sponsor · 2024-12-05
COMPLETED
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting ConditionsNCT06890286 · lead sponsor · 2024-12-01
COMPLETED
A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting ConditionsNCT06879158 · lead sponsor · 2024-11-10
COMPLETED
A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fed ConditionsNCT06879132 · lead sponsor · 2024-11-05
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy VolunteersNCT06636877 · lead sponsor · 2024-10-23
COMPLETED
A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult VolunteersNCT06889064 · lead sponsor · 2024-09-24
COMPLETED
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination TherapyNCT06220773 · lead sponsor · 2024-05-21
UNKNOWN
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018CNCT06165250 · lead sponsor · 2024-04-17
COMPLETED
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fed Conditions in Healthy Adult VolunteersNCT06289933 · lead sponsor · 2024-03-05
COMPLETED
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult VolunteersNCT06289920 · lead sponsor · 2024-03-02
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"NCT06226727 · lead sponsor · 2024-02-14
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B"NCT06184269 · lead sponsor · 2023-12-23
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy VolunteersNCT06008015 · lead sponsor · 2023-09-04
COMPLETED
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy VolunteersNCT06008028 · lead sponsor · 2023-08-10
COMPLETED
A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy VolunteersNCT05951946 · lead sponsor · 2023-07-22
COMPLETED
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary HypercholesterolemiaNCT05930028 · lead sponsor · 2023-07-13
COMPLETED
A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult SubjectsNCT05875259 · lead sponsor · 2023-05-13
COMPLETED
A Study to Evaluate the Efficacy and Safety of BR1015 Combination TherapyNCT05878561 · lead sponsor · 2022-11-09
COMPLETED
A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult SubjectsNCT05460364 · lead sponsor · 2022-08-04
COMPLETED
A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy VolunteersNCT05372380 · lead sponsor · 2022-05-09
COMPLETED
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.NCT05411965 · lead sponsor · 2022-04-28
COMPLETED
A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016C" With "BR1016D" in Healthy VolunteersNCT05102266 · lead sponsor · 2021-10-27
COMPLETED
A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016A" With "BR1016B" in Healthy VolunteersNCT05102903 · lead sponsor · 2021-10-22
COMPLETED
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and ProteinuriaNCT05086549 · lead sponsor · 2021-09-29
COMPLETED
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)NCT05102305 · lead sponsor · 2021-09-09
COMPLETED
A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy VolunteersNCT05097794 · lead sponsor · 2021-08-16
COMPLETED
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinNCT04885712 · lead sponsor · 2021-05-28
COMPLETED
A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male VolunteersNCT04889651 · lead sponsor · 2021-04-15
COMPLETED
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)NCT04770454 · lead sponsor · 2021-02-08
COMPLETED
Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating FactorNCT04545632 · lead sponsor · 2020-06-10
COMPLETED
A Study to Compare the Pharmacokinetics of BR4002 and BR4002-1 in Healthy VolunteersNCT04462029 · lead sponsor · 2020-06-05
COMPLETED
A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and DyslipidemiaNCT04554953 · lead sponsor · 2020-04-13
COMPLETED
BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine CombinationNCT03991442 · lead sponsor · 2019-06-17
COMPLETED
To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy SubjectsNCT03718611 · lead sponsor · 2018-10-22
COMPLETED
Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male SubjectsNCT03629067 · lead sponsor · 2018-09-13
COMPLETED
A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy VolunteersNCT03609294 · lead sponsor · 2018-07-18
COMPLETED
FimasaRtan-basEd BP Targets After Drug SwitcHingNCT03649646 · lead sponsor · 2018-07-03
COMPLETED
A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and DyslipidemiaNCT03338426 · lead sponsor · 2018-01-15
COMPLETED
A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male VolunteersNCT03250052 · lead sponsor · 2017-08-14
COMPLETED
Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE StudyNCT03254914 · lead sponsor · 2017-08-09
COMPLETED

Drugs studied in this sponsor's trials

13 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Boryung Pharmaceutical Co., Ltd as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
rosuvastatin6
placebo4
amlodipine3
atorvastatin3
pioglitazone 30 MG3
valsartan3
dapagliflozin 10 MG2
hydrochlorothiazide2
rosuvastatin RxCUI 301542 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 6 trials placebo RxCUI 8375 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials amlodipine RxCUI 17767 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials atorvastatin RxCUI 83367 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials pioglitazone 30 MG RxCUI 331478 · Lead sponsor in 3 linked trial(s) · 2 currently recruiting 3 trials valsartan RxCUI 69749 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials dapagliflozin 10 MG RxCUI 1488565 · Lead sponsor in 2 linked trial(s) · 2 currently recruiting 2 trials hydrochlorothiazide RxCUI 5487 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials atenolol RxCUI 1202 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial candesartan cilexetil RxCUI 135481 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial losartan RxCUI 52175 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial metformin RxCUI 6809 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial olmesartan medoxomil RxCUI 118463 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor106
collaborator5
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.